iFabric Corp Reports Record Revenue and Earnings for Q1 2026

iFabric Corp. reported record Q1 2026 revenues of $27.5 million, a 288% increase year-over-year, driven by the Intelligent Fabrics Division’s medical apparel and footwear programs, and the launch of the Nudish™ brand following the Maidenform® license expiration. Net earnings after tax soared to $3.71 million ($0.122 per share) compared to $88,458 a year ago. Adjusted EBITDA reached $5.73 million, a dramatic swing from $0.32 million in Q1 2025. Gross margin was 33%, impacted by product mix and tariffs; the company initiated a claim to recover ~$850,000 in IEEPA tariffs. Cash stood at $1.76 million, down from $3.78 million at year-end, due to inventory build. CEO Hylton Karon emphasized the strength of the innovation pipeline and retail execution.

The Q1 2026 revenue of $27.5M came in at the high end of management’s raised guidance of $25M–$27M (issued March 31, 2026), essentially as expected. What makes this news material is the earnings and EBITDA outperformance: net income of $3.71M ($0.122/sh) and an adjusted EBITDA margin of ~20.8%—well above the company’s full‑year 2026 target of 15% and orders of magnitude better than prior periods. This demonstrates significant operating leverage and faster‑than‑anticipated margin recovery, even though gross margin (33%) has not yet hit the 35–37% target. The bottom‑line beat is genuinely new and market‑moving for a company of this size, especially given that the stock had pulled back to $3.75 from $4.42 ahead of the release. This news validates the scalability of the intelligent fabrics platform and should positively re‑rate the shares.

iFabric Corp., through its subsidiary Intelligent Fabric Technologies (North America) Inc. (IFTNA), develops and markets high‑performance textile treatments—principally PROTX2® antimicrobial/anti‑odor and ecoPEL™ water‑repellent finishes. The flagship project is a clinically‑proven medical scrubs program sold through major retailers (Walmart, Costco) under proprietary and licensed brands (Frontline™, Doctor’s Choice®). The company has expanded into intimate apparel (Nudish™ own brand replacing Maidenform) and footwear (Roots®). A peer‑reviewed clinical trial published in the Journal of Hospital Infection supports the scrubs’ infection‑control claims.